Regulators in Japan Asked to Extend Hemlibra to Acquired Hemophilia A

Regulators in Japan Asked to Extend Hemlibra to Acquired Hemophilia A

311823

Regulators in Japan Asked to Extend Hemlibra to Acquired Hemophilia A

Chugai Pharmaceutical is asking regulatory authorities in Japan to extend the use of Hemlibra (emicizumab) in preventing or reducing the frequency of bleeding episodes to people with acquired hemophilia A. Hemophilia A is caused by genetic mutations that make the body unable to produce a fully functional version of the factor VIII (FVIII) clotting protein. In acquired hemophilia A, low levels of FVIII result from the immune system erroneously attacking and destroying the protein, rather than…

You must be logged in to read/download the full post.